448 related articles for article (PubMed ID: 25287328)
21. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
[TBL] [Abstract][Full Text] [Related]
22. FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.
McKeen HD; Byrne C; Jithesh PV; Donley C; Valentine A; Yakkundi A; O'Rourke M; Swanton C; McCarthy HO; Hirst DG; Robson T
Cancer Res; 2010 Feb; 70(3):1090-100. PubMed ID: 20103631
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
24. The G-protein-coupled estrogen receptor, a gene co-expressed with ERα in breast tumors, is regulated by estrogen-ERα signalling in ERα positive breast cancer cells.
Pal U; Manjegowda MC; Singh N; Saikia S; Philip BS; Jyoti Kalita D; Kumar Rai A; Sarma A; Raphael V; Modi D; Chandra Kataki A; Mukund Limaye A
Gene; 2023 Aug; 877():147548. PubMed ID: 37279863
[TBL] [Abstract][Full Text] [Related]
25. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
27. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
[TBL] [Abstract][Full Text] [Related]
28. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
29. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
Morrison MM; Williams MM; Vaught DB; Hicks D; Lim J; McKernan C; Aurisicchio L; Ciliberto G; Simion C; Sweeney C; Cook RS
Oncogene; 2016 Mar; 35(9):1143-52. PubMed ID: 26148232
[TBL] [Abstract][Full Text] [Related]
30. Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach.
Santos-Martínez N; Díaz L; Ordaz-Rosado D; García-Quiroz J; Barrera D; Avila E; Halhali A; Medina-Franco H; Ibarra-Sánchez MJ; Esparza-López J; Camacho J; Larrea F; García-Becerra R
BMC Cancer; 2014 Mar; 14():230. PubMed ID: 24678876
[TBL] [Abstract][Full Text] [Related]
31. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.
Thewes V; Simon R; Hlevnjak M; Schlotter M; Schroeter P; Schmidt K; Wu Y; Anzeneder T; Wang W; Windisch P; Kirchgäßner M; Melling N; Kneisel N; Büttner R; Deuschle U; Sinn HP; Schneeweiss A; Heck S; Kaulfuss S; Hess-Stumpp H; Okun JG; Sauter G; Lykkesfeldt AE; Zapatka M; Radlwimmer B; Lichter P; Tönjes M
Oncogene; 2017 Jul; 36(29):4124-4134. PubMed ID: 28319069
[TBL] [Abstract][Full Text] [Related]
32. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
33. A novel function of the Fe65 neuronal adaptor in estrogen receptor action in breast cancer cells.
Sun Y; Kasiappan R; Tang J; Webb PL; Quarni W; Zhang X; Bai W
J Biol Chem; 2014 May; 289(18):12217-31. PubMed ID: 24619425
[TBL] [Abstract][Full Text] [Related]
34. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Martin LA; Pancholi S; Chan CM; Farmer I; Kimberley C; Dowsett M; Johnston SR
Endocr Relat Cancer; 2005 Dec; 12(4):1017-36. PubMed ID: 16322340
[TBL] [Abstract][Full Text] [Related]
35. Expression of estrogen receptor alpha with a Tet-off adenoviral system induces G0/G1 cell cycle arrest in SKBr3 breast cancer cells.
Peng J; Jordan VC
Int J Oncol; 2010 Feb; 36(2):451-8. PubMed ID: 20043081
[TBL] [Abstract][Full Text] [Related]
36. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
37. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
[TBL] [Abstract][Full Text] [Related]
38. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
39. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
[TBL] [Abstract][Full Text] [Related]
40. Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer.
Xu L; Kwon YJ; Frolova N; Steg AD; Yuan K; Johnson MR; Grizzle WE; Desmond RA; Frost AR
Breast Cancer Res Treat; 2010 Aug; 123(1):59-71. PubMed ID: 19902354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
